These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma. Park JS; Oh Y; Park YJ; Park O; Yang H; Slania S; Hummers LK; Shah AA; An HT; Jang J; Horton MR; Shin J; Dietz HC; Song E; Na DH; Park EJ; Kim K; Lee KC; Roschke VV; Hanes J; Pomper MG; Lee S Nat Commun; 2019 Mar; 10(1):1128. PubMed ID: 30850660 [TBL] [Abstract][Full Text] [Related]
25. Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Lakos G; Takagawa S; Chen SJ; Ferreira AM; Han G; Masuda K; Wang XJ; DiPietro LA; Varga J Am J Pathol; 2004 Jul; 165(1):203-17. PubMed ID: 15215176 [TBL] [Abstract][Full Text] [Related]
26. A convenient method for producing the bleomycin-induced mouse model of scleroderma by weekly injections using a methylcellulose gel. Jun JB; Kim JK; Na YI; Jang SM; Paik SS; Kim YH Rheumatol Int; 2012 May; 32(5):1443-7. PubMed ID: 21448642 [TBL] [Abstract][Full Text] [Related]
27. Loss of beta1 integrin in mouse fibroblasts results in resistance to skin scleroderma in a mouse model. Liu S; Kapoor M; Denton CP; Abraham DJ; Leask A Arthritis Rheum; 2009 Sep; 60(9):2817-21. PubMed ID: 19714619 [TBL] [Abstract][Full Text] [Related]
28. TRPA1 as a potential factor and drug target in scleroderma: dermal fibrosis and alternative macrophage activation are attenuated in TRPA1-deficient mice in bleomycin-induced experimental model of scleroderma. Mäki-Opas I; Hämäläinen M; Moilanen E; Scotece M Arthritis Res Ther; 2023 Jan; 25(1):12. PubMed ID: 36698198 [TBL] [Abstract][Full Text] [Related]
29. Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Kapoor M; McCann M; Liu S; Huh K; Denton CP; Abraham DJ; Leask A Arthritis Rheum; 2009 Sep; 60(9):2822-9. PubMed ID: 19714649 [TBL] [Abstract][Full Text] [Related]
30. Effects of thalidomide on Th17, Treg cells and TGF-β1/Smad3 pathway in a mouse model of systemic sclerosis. Lu Y; Zhao C; Lei L; Tao Z; Zheng L; Wen J; Li X Int J Rheum Dis; 2020 Mar; 23(3):406-419. PubMed ID: 31840939 [TBL] [Abstract][Full Text] [Related]
31. Oligosaccharide modification by N-acetylglucosaminyltransferase-V in macrophages are involved in pathogenesis of bleomycin-induced scleroderma. Kato A; Yutani M; Terao M; Kimura A; Itoi S; Murota H; Miyoshi E; Katayama I Exp Dermatol; 2015 Aug; 24(8):585-90. PubMed ID: 25876794 [TBL] [Abstract][Full Text] [Related]
32. Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice. Taniguchi T; Asano Y; Akamata K; Noda S; Takahashi T; Ichimura Y; Toyama T; Trojanowska M; Sato S Arthritis Rheumatol; 2015 Feb; 67(2):517-26. PubMed ID: 25385187 [TBL] [Abstract][Full Text] [Related]
33. Amelioration of tissue fibrosis by toll-like receptor 4 knockout in murine models of systemic sclerosis. Takahashi T; Asano Y; Ichimura Y; Toyama T; Taniguchi T; Noda S; Akamata K; Tada Y; Sugaya M; Kadono T; Sato S Arthritis Rheumatol; 2015 Jan; 67(1):254-65. PubMed ID: 25302613 [TBL] [Abstract][Full Text] [Related]
34. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis. Manetti M; Romano E; Rosa I; Guiducci S; Bellando-Randone S; De Paulis A; Ibba-Manneschi L; Matucci-Cerinic M Ann Rheum Dis; 2017 May; 76(5):924-934. PubMed ID: 28062404 [TBL] [Abstract][Full Text] [Related]
35. Secukinumab and metformin ameliorate dermal fibrosis by decreasing tissue interleukin-17 levels in bleomycin-induced dermal fibrosis. Karatas A; Celik C; Oz B; Akar ZA; Etem EO; Dagli AF; Koca SS Int J Rheum Dis; 2021 Jun; 24(6):795-802. PubMed ID: 33835703 [TBL] [Abstract][Full Text] [Related]
36. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis. Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591 [TBL] [Abstract][Full Text] [Related]
37. Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma. Aung WW; Wang C; Xibei J; Horii M; Mizumaki K; Kano M; Okamura A; Kobayashi T; Matsushita T J Dermatol Sci; 2021 Mar; 101(3):174-184. PubMed ID: 33451905 [TBL] [Abstract][Full Text] [Related]
38. Protective role of NKT cells and macrophage M2-driven phenotype in bleomycin-induced pulmonary fibrosis. Grabarz F; Aguiar CF; Correa-Costa M; Braga TT; Hyane MI; Andrade-Oliveira V; Landgraf MA; Câmara NOS Inflammopharmacology; 2018 Apr; 26(2):491-504. PubMed ID: 28779430 [TBL] [Abstract][Full Text] [Related]
40. MKP-1 Deficiency Exacerbates Skin Fibrosis in a Mouse Model of Scleroderma. Scotece M; Hämäläinen M; Leppänen T; Vuolteenaho K; Moilanen E Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902103 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]